






License: Article 25fa pilot End User Agreement 
This publication is distributed under the terms of Article 25fa of the Dutch Copyright Act (Auteurswet) 
with explicit consent by the author. Dutch law entitles the maker of a short scientific work funded either 
wholly or partially by Dutch public funds to make that work publicly available for no consideration 
following a reasonable period of time after the work was first published, provided that clear reference is 
made to the source of the first publication of the work.  
This publication is distributed under The Association of Universities in the Netherlands (VSNU) ‘Article 
25fa implementation’ pilot project. In this pilot research outputs of researchers employed by Dutch 
Universities that comply with the legal requirements of Article 25fa of the Dutch Copyright Act are 
distributed online and free of cost or other barriers in institutional repositories. Research outputs are 
distributed six months after their first online publication in the original published version and with proper 
attribution to the source of the original publication.  
You are permitted to download and use the publication for personal purposes. All rights remain with the 
author(s) and/or copyrights owner(s) of this work. Any use of the publication other than authorised under 
this licence or copyright law is prohibited. 
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, 
please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make 





Gianessi C.A., Groman S.M., Thompson S.L., Jiang M., Stelt M. van der & Taylor J.R. (2019), 
Endocannabinoid contributions to alcohol habits and motivation: Relevance to treatment, 
Addiction Biology : e12768. 
Doi: 10.1111/adb.12768 
Received: 9 November 2018 Revised: 26 February 2019 Accepted: 1 April 2019
DOI: 10.1111/adb.12768OR I G I N A L A R T I C L EEndocannabinoid contributions to alcohol habits and
motivation: Relevance to treatmentCarol A. Gianessi1,2 | Stephanie M. Groman1 | Summer L. Thompson1 | Ming Jiang3 |
Mario van der Stelt3 | Jane R. Taylor1,2,41Department of Psychiatry, Division of
Molecular Psychiatry, Yale University School of
Medicine, New Haven, CT, USA
2 Interdepartmental Neuroscience Program,
Yale University Graduate School of Arts and
Sciences, New Haven, CT, USA
3Department of Molecular Physiology, Leiden
Institute of Chemistry, Leiden University,
Leiden, The Netherlands
4Department of Psychology, Yale University,
New Haven, CT, USA
Correspondence
Jane R. Taylor, Department of Psychiatry, 34




Charles B.G. Murphy Fund; National Alliance
for Research on Schizophrenia and Depres-
sion; National Institute on Alcohol Abuse and
Alcoholism, Grant/Award Number: AA012870;
National Institute on Drug Abuse, Grant/
Award Numbers: DA041480 and DA043443;
State of CT Department of Mental Health
ServicesAddiction Biology. 2019;e12768.
https://doi.org/10.1111/adb.12768Abstract
Individuals with alcohol use disorder exhibit compulsive habitual behaviors that are
thought to be, in part, a consequence of chronic and persistent use of alcohol. The
endocannabinoid system plays a critical role in habit learning and in ethanol self‐
administration, but the role of this neuromodulatory system in the expression of
habitual alcohol seeking is unknown. Here, we investigated the role of the
endocannabinoid system in established alcohol habits using contingency degradation
in male C57BL/6 mice. We found that administration of the novel diacyl glycerol
lipase inhibitor DO34, which decreases the biosynthesis of the endocannabinoid 2‐
arachidonoyl glycerol (2‐AG), reduced habitual responding for ethanol and ethanol
approach behaviors. Moreover, administration of the endocannabinoid transport
inhibitor AM404 or the cannabinoid receptor type 1 antagonist AM251 produced
similar reductions in habitual responding for ethanol and ethanol approach behaviors.
Notably, AM404 was also able to reduce ethanol seeking and consumption in mice
that were insensitive to lithium chloride‐induced devaluation of ethanol. Conversely,
administration of JZL184, a monoacyl glycerol lipase inhibitor that increases levels of
2‐AG, increased motivation to respond for ethanol on a progressive ratio schedule of
reinforcement. These results demonstrate an important role for endocannabinoid sig-
naling in the motivation to seek ethanol, in ethanol‐motivated habits, and suggest
that pharmacological manipulations of endocannabinoid signaling could be effective
therapeutics for treating alcohol use disorder.
KEYWORDS
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Alcohol use disorder (AUD) is characterized by the inability to restrict
alcohol drinking despite the persistent desire, yet unsuccessful efforts,
to cut down or control alcohol use. Habits are defined as actions that
happen automatically in response to antecedent environmental stimuli
and are insensitive to changes in the desirability of the outcome. Dif-
ficulties in abstaining from alcohol—despite persistent desire to do so
—can be thought of as habitual because drinking behavior iswileyonlinelibrary.com/journal/insensitive to changes in the desirability of alcohol for individuals with
AUD. Accordingly, a transition to habitual responding for alcohol is
hypothesized to contribute to the compulsive patterns of alcohol‐
seeking and consumption that are characteristic of AUD.1-3 Moreover,
people with AUD show an overreliance on habitual responding in lab-
oratory tasks,4-6 and this strong habitual behavioral control in general
is hypothesized to extend to alcohol‐motivated behavior. If strong
habitual control over alcohol consumption is a core pathological com-
ponent of AUD, then pharmacological compounds that reduce the© 2019 Society for the Study of Addictionadb 1 of 12
2 of 12 GIANESSI ET AL.expression of well‐established alcohol (i.e., ethanol) habits in mice may
have translational relevance to mitigate compulsive alcohol seeking
in AUD.
Habitual behavior depends on the functioning of the dorsolateral
striatum and connected cortico‐basal ganglia networks,7,8 which are
highly conserved across species.9,10 Robust expression of presynaptic
cannabinoid receptor type 1 (CB1) in the dorsolateral striatum contrib-
utes to forms of short‐term and long‐term plasticity.11,12 It is hypoth-
esized that these forms of plasticity are important for habit
formation.13 Indeed, transgenic animals with CB1 receptors knocked
out globally or within specific nodes of the dorsal striatal network
have impaired habit formation.14,15 Chronic exposure to ethanol alters
plasticity in the dorsolateral striatal network, strengthening its control
over behavior,16-18 which may promote habitual control over alcohol
seeking. Therefore, the CB1 receptor dysregulation that has been
observed in alcohol‐dependent individuals19,20 may be a key mecha-
nism by which habitual alcohol use persists in AUD.
Support for this hypothesis comes from evidence demonstrating
that pharmacological manipulations of CB1 receptors bidirectionally
alter ethanol self‐administration: CB1 agonists increase, whereas
CB1 receptor antagonists decrease, self‐administration of ethanol,
and motivation for ethanol.21 The two most studied endocannabinoid
ligands are anandamide and 2‐arachidonoyl glycerol (2‐AG).22 There is
evidence indicating that 2‐AG is released following administration of
ethanol, and that the magnitude of 2‐AG release is higher for self‐
administered than experimenter‐administered ethanol.23,24 Moreover,
the magnitude of 2‐AG release is correlated with the amount of etha-
nol consumed in self‐administration.24 This suggests that 2‐AG release
may, in part, encode the motivation to consume ethanol. Although it is
currently unknown which endocannabinoid ligand contributes to the
necessity of CB1 receptors to habit formation, it is likely that height-
ened 2‐AG signaling at the CB1 receptor contributes to the plasticity
underlying the formation of habitual response strategies for ethanol.
Here, we investigated the role for the endocannabinoid system in
the expression of habitual responding for ethanol in mice. Using an
extended ethanol self‐administration habit model, we tested the novel
compound, DO34, that degrades the primary enzyme that synthesizes
2‐AG.25,26 We observed a reduction in habitual responding for ethanol
and ethanol approach behavior using a contingency degradation para-
digm. Furthermore, we observed similar reductions in habitual
responding for ethanol following administration of a CB1 receptor
antagonist, AM251, and following administration of the putative
endocannabinoid transport inhibitor AM404.27-29 We observed no
effect of pharmacologically increasing anandamide or 2‐AG on habit-
ual responding for ethanol. Consequently, we hypothesized that
reduced habitual responding for ethanol was likely due to a reduction
in CB1 receptor‐mediated signaling via a reduction in 2‐AG release.
Because these drug manipulations reduced both habitual ethanol
seeking responses and approach behaviors for ethanol, the release of
2‐AG may encode the motivation to seek and consume ethanol.
Indeed, we report that administration of JZL184, an inhibitor of the
metabolic enzyme for 2‐AG, dose‐dependently increased motivation
for ethanol using a progressive ratio schedule of reinforcement.Together, our data provide new evidence that 2‐AG release may con-
tribute to the motivation for ethanol, and that pharmacological manip-
ulations to reduce 2‐AG release or moderate activation of the CB1
receptor can decrease habitual ethanol seeking and approach
behavior.2 | MATERIALS AND METHODS
2.1 | Animals
Adult male C57BL/6N mice (Charles River Laboratories; Wilmington,
MA) were used for all experiments. Males were selected because they
are known to form ethanol habits at a faster rate than female mice.30
Mice were delivered at 7 to 8 weeks of age, group‐housed in standard
cages on ventilation racks (Tecniplast; West Chester, PA) within a
climate‐controlled vivarium, maintained on a 12‐hour light/dark cycle
(lights on at 0700 hours). Following 7 days of acclimation to the vivar-
ium, access to food was restricted, and mice were maintained at 85%
to 90% of free‐feeding body weight for the duration of the experi-
ment. Mice were fed 2.0 to 3.0 g of standard rodent chow (2918
Teklad diet, Envigo, Huntingdon, United Kingdom) per mouse per
day. Water was available ad libitum in the home cage but was removed
prior to behavioral testing. Mice were fed for 15 minutes without
water available before behavioral sessions to induce thirst. Before
beginning instrumental training, mice were exposed to ad libitum
10% ethanol, 0.1% saccharin solution in their home cage for 2 days
in 1‐hour sessions. Intake was measured to ensure that all animals
consumed ethanol and to reduce neophobia to the ethanol solution.
All behavioral procedures were approved by the Yale University Insti-
tutional Animal Care and Use Committee and were in accordance with
the National Institutes of Health Guide for the Care and Use of Labora-
tory Animals of the Institute of Laboratory Animal Resources.2.1.1 | Drugs
The diacyl glycerol lipase inhibitor DO34 and the comparison com-
pound DO53 were synthesized as previously described.25,26 Lithium
chloride (Sigma‐Aldrich [St. Louis, MO]) was dissolved at 0.15 M in
saline and injected at 40 mL/kg.30
All endocannabinoid drugs were dissolved in 5% DMSO, 15%
Tween 80 in sterile physiological saline, except DO34 and DO53,
which were dissolved in 5% DMSO 15% kolliphor in saline. All
endocannabinoid drugs were administered via intraperitoneal injection
at 10 mL/kg. DO34 and DO53 were administered at 50 mg/kg
because they have previously been shown to decrease food intake
at these doses.25 AM404 (R&D Systems [Minneapolis, MN] and Fisher
Scientific [Waltham, MA]) was administered at 10 mg/kg, a dose
reported to decrease presumably goal‐directed ethanol self‐
administration.31 AM251 (Fisher Scientific) was administered at
1 mg/kg based on our previous work demonstrating reduced habitual
food seeking at this dose.32 JZL184 (Sigma‐Aldrich and Cayman
Chemical [Ann Arbor, MI]) was administered at 2, 8, and 18 mg/kg
GIANESSI ET AL. 3 of 12based on previously reported effects on habitual food seeking (2 and
18 mg/kg)32 and anxiety‐like behavior (8 mg/kg).33 URB597 (Sigma‐
Aldrich) was administered at 0.5 mg/kg.342.1.2 | Behavioral training
Behavioral apparatus and training
Behavior was assessed in standard operant conditioning chambers
located within sound‐attenuated boxes (Med Associates; St. Albans,
VT), which were identical to those described previously.30 Each cham-
ber was equipped with three nosepoke apertures located on the back
wall, with a magazine positioned in the center of the front wall.
Nosepoke apertures and magazine were each equipped with a light
and with a photobeam sensor to record entries. A fan provided venti-
lation and background noise throughout the behavioral sessions. Liq-
uid reinforcers (10% ethanol v/v, 0.1% saccharin) were presented
using a dipper arm that delivered a 10‐μL cup of the reinforcer into
the magazine. When the dipper arm was raised, magazine entries were
recorded as a proxy for ethanol consumption—these entries are
referred to as “incentivized entries.” Total magazine entries are
reported to measure ethanol approach.
Mice underwent 2 days of magazine training to habituate to the
operant chambers and to learn the association between ethanol deliv-
ery and the magazine. Sixty seconds after the start of the behavioral
session, the dipper of ethanol reinforcer became available. The dipper
remained available until the mouse entered the magazine and
retracted after 10 seconds. Following a 60‐second intertrial interval,
the dipper became available for 10 seconds after a magazine entry,
and this was repeated throughout the 40‐minute session.
Following magazine training, mice underwent operant training.
One nosepoke aperture, either the left or the right, was assigned to
deliver reward (referred to as “active”), and the other two apertures
had no programmed consequence (referred to as “inactive”). Assign-
ment of active aperture was counterbalanced across mice and main-
tained throughout the duration of the experiment. Training sessions
began with the illumination of the active nosepoke and ended with
the light extinguishing.
Active aperture entries were initially reinforced using a fixed ratio
1 (FR1) schedule, where each entry resulted in delivery of a single
reinforcer. These FR1 sessions began with one free dipper that
remained available until the mouse entered the magazine and
retracted 10 seconds after. Subsequent reinforcers were earned with
active responses. Dippers earned during FR1 training sessions
remained available until the mouse made an entry into the magazine
and then retracted 10 seconds later. FR1 sessions terminated when
mice earned 60 dippers, or 45 min elapsed, whichever occurred first.
Once individual mice earned 13 dippers of ethanol solution in a single
FR1 session (5‐13 days), they were then trained on a variable interval
(VI) schedule of reinforcement. Mice that required 6 or more days to
achieve the performance criterion underwent remedial FR1 sessions
that were extended to a duration of 2 hours. Mice that took >13 days
to reach FR1 criteria were excluded (n = 19 excluded out of n = 111
for all experiments).Oncemice achieved the performance criterion on the FR1 schedule,
VI training began. VI schedules were determined by randomly selecting
the duration of the interval from an exponential array32 that had an
average of 30 seconds for the VI30 schedule and an average of 60 sec-
onds for the VI60 schedule. The first active nosepoke response made
after the interval elapsed resulted in delivery of the dipper full of etha-
nol solution. During VI sessions, dippers were available for 10 seconds
following the active response, regardless of whether the mouse
entered the magazine. The duration of the next interval was then ran-
domly selected from the exponential array. This continued for the dura-
tion of the 45‐minute session. Mice received 3 days of VI30 training
and were subsequently trained on a VI60 schedule for at least 21 days.
Contingency degradation test
Contingency degradation tests were conducted as previously
described.32,35 Briefly, these sessions appeared similar to the operant
training session, but dippers of ethanol were noncontingently deliv-
ered. Active aperture responses had no programmed consequence.
Dippers were delivered at equal intervals, matching the total number
of ethanol reinforcers mice earned the day prior. Sessions terminated
when 45 minutes had elapsed.
For most experiments, the first contingency degradation test was
administered following 21 days of VI60 training to confirm that
responding was habitual (see statistical analysis below) prior to any
pharmacological intervention. Following each test, mice received addi-
tional VI60 sessions to stabilize response rates before additional test-
ing. Cohorts that were not habitual on their first contingency
degradation test received additional VI60 training (3‐10 days), until
habitual responding was confirmed.
Individual logistic regression analysis
We applied a novel statistical technique for classifying individual ani-
mals' pattern of responding as goal‐directed or habitual.32 Response
rate for each mouse during the contingency degradation session was
compared with that mouse's response rate for all previous VI60 ses-
sions using a generalized linear model (GLM) with a Poisson distribu-
tion, which is the most appropriate distribution for count data. A
session‐type regressor (ie, VI60 session coded as 0, test coded as 1)
and a linear covariate regressor were included. Mice with significant
negative regression coefficients for the session‐type regressor were
classified as goal‐directed, because a significant negative regression
coefficient indicates that the decrease in responding during the test
session was beyond the normal range of variability in response rates
on VI60 sessions for that animal. In contrast, mice with a nonsignifi-
cant or positive coefficient for the session‐type regressor were classi-
fied as habitual, because a nonsignificant or positive coefficient
indicates that responding had not substantially decreased during the
test session. Only mice confirmed to be habitual were included in
the pharmacological studies.
Pharmacological studies
Following confirmation of habitual responding and re‐establishment of
stable responding on the VI60 schedule (2‐8 days), the
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prior to the VI60 session on the day immediately before the contin-
gency degradation tests with pharmacological manipulations. This
served as the nondegraded operant session (referred to as “Baseline”).
If vehicle administration drastically reduced the number of rewards
earned compared with previous VI60 sessions, mice underwent addi-
tional training on the VI60 schedule (2‐14 days) until rewards earned
in the Baseline were approximately equivalent to previous sessions.
The day after completing the Baseline session, drug was administered
and responding was assessed in a contingency degradation test.
AM404, AM251, and the vehicle conditions for those experiments
were administered 30 minutes prior to the session as reported previ-
ously.31 JZL184, URB597, DO34, DO53, and their respective vehicle
conditions were administered 2 hours prior to the behavioral session
as reported previously.25,33 Drug order was counterbalanced with a
Latin square for all experiments, except for the DO34 experiment,
where vehicle or DO34 were given in a counterbalanced order, with
the control compound DO53 administered as the final condition for
all animals. This design was used to avoid any potential carryover
effects from previous drug administration that might impact
responding following administration of DO34.
Lithium chloride devaluation experiment
Habitual behavior is defined by a loss of representation of the action‐
outcome relationship, which can be tested for by contingency degrada-
tion, and by a loss of sensitivity to the value of the outcome, which can
be tested for by reinforcer devaluation. Following assessment of
effects of AM404 on habitual ethanol seeking during contingency deg-
radation, habitual responding was further assessed using lithium chlo-
ride (LiCl) devaluation as an additional test for habitual behavior.
Following completion of counterbalanced contingency degradation
tests with vehicle and AM404, mice were assigned to groups (devalued
or valued) balanced according to prior response rates during the contin-
gency degradation test following administration of AM404. The lithium
chloride devaluation procedures have been described elsewhere.30
Mice were fed at least 3.5 hours prior to being placed in a novel cage
for a 30‐minute exposure to ad libitum 10% ethanol, 0.1% saccharin
solution. Immediately following removal from the cage, devalued group
mice were injected with LiCl, and the nondevalued group with saline.
Three hours after the ethanol exposure, mice received a crossover
injection in order to counterbalance the experience of malaise. These
devaluation procedures were repeated for 3 days. Devaluation was
assessed the following day with a habitual responding test and a condi-
tioned taste aversion test. First, in the habitual responding test, mice
were returned to the operant chamber for a 5‐minute session in extinc-
tion, where the active nosepoke was illuminated, but had no pro-
grammed response. Conditioned taste aversion was confirmed
directly after the habitual responding test, in a novel cage with access
to ad libitum 10% ethanol, 0.1% saccharin solution for 30 minutes.
Progressive ratio experiment
We hypothesize that 2‐AG release contributes to the motivation for
ethanol, so to directly test this hypothesis we examined whetherincreasing 2‐AG levels with JZL184 administration prior to a progres-
sive ratio paradigm would increase motivation. A separate cohort of
mice was trained on the progressive ratio schedule of reinforcement
after achieving the FR1 performance criterion described above. This
ratio schedule followed the formula: response ratio = (5*e0.2*dipper)‐5,
rounded up to the nearest integer as described previously (e.g., 36).
This task was modified for ethanol reinforcers by changing the session
timeout to 504 seconds from the last active response, which was
three times the average inter‐reinforcer interval during FR1 self‐
administration.37 The last ratio that the mouse completed is referred
to as the “breakpoint” and is thought to be an index of the motivation
for the reinforcer. Because breakpoint is not a continuous measure,
we report rewards earned, which is proportional to the log‐
transformed breakpoint.37 Mice underwent several days on the pro-
gressive ratio schedule until they achieved the same breakpoint on
two sequential days. Animals that took >10 days to achieve a stable
breakpoint were excluded from the experiment (n = 5). The remaining
animals (n = 12) took 5 to 10 days to stabilize for the first time on the
progressive ratio schedule of reinforcement, and there were 2 to
9 days between drug conditions. Data from each progressive ratio ses-
sion following drug administration were compared with the drug‐free
progressive ratio session from the previous day, referred to as “Base-
line,” and to data from the vehicle treatment session.2.2 | Statistical analysis
Data were analyzed using Prism 7 (Graphpad, San Diego, CA), SPSS 21
(IBM, Armonk, NY), and MATLAB 2016b (MathWorks, Natick, MA).
Data are presented as the mean ± standard error of the mean (SEM),
unless otherwise specified. Our threshold for significance was set at
P < .05. Response rates, total magazine entries, and incentivized
entries were analyzed using repeated measures GLM with a Poisson
distribution. Regression coefficients were tested with Wald χ2 to
determine if they were significantly different from zero. Significant
interactions were followed up using post hoc, pairwise comparisons
with Sidak adjustment for multiple comparisons.3 | RESULTS
3.1 | Measuring the impact of 2‐AG release on
habitual responding
2‐AG levels have been reported to increase after ethanol administra-
tion,23,24 so we sought to determine if inhibiting 2‐AG release reduced
habitual responding for ethanol. We examined the effect of the novel
compound DO34, which is an inhibitor of diacyl glycerol lipases
(DAGLα and DAGLβ), the enzymes that synthesize 2‐AG, on habitual
responding for ethanol. Because DO34 is not completely selective
for DAGLs, but also inhibits ABHD6, we compared the effect of
DO34 to a control compound, DO53, which shares the same off‐
target activity as DO34 but does not inhibit DAGLs.25,26 The experi-
mental timeline for measuring the impact of DO34 on habitual
GIANESSI ET AL. 5 of 12responding for ethanol is presented in Figure 1A. Active response
rates increased across VI30 and VI60 sessions (Figure 1B). We then
conducted a contingency degradation test and classified mice
(n = 16) as goal‐directed or habitual based on our individual regression
analyses, ensuring all mice were habitual prior to pharmacological test-
ing. DO34 significantly reduced response rates in the contingency
degradation test compared with vehicle‐administration (Figure 1C;
P < .001), whereas the control compound DO53 was not different
from vehicle administration (P = .6). During the DO34 condition, mice
made significantly fewer magazine entries (Figure 1D; main effect of
DO34: χ2 = 10.9, P = .001), but magazine entries following administra-
tion of the control compound DO53 were not significantly different
from vehicle (main effect of DO53: χ2 = 0.3, P = .6). No effects of drug
were observed for incentivized entries (Figure 1E) or inactive
responses (Figure 1F).FIGURE 1 Decreasing 2‐AG biosynthesis reduces habitual responding for
earned ethanol (g/kg, right axis) across operant ethanol training. C, Active
DO53, and vehicle treatment within‐subjects, n = 16. Main effect of session
by‐drug interaction: χ2 = 61.7, P < .001. D, Total magazine entries during
treatment within‐subjects, n = 16. Main effect of session: χ2 = 9.8, P = .002
χ2 = 2.0, P = .4. E, Incentivized entries into the magazine during contingenc
subjects, n = 16. Main effect of session: χ2 = 0.07, P = .8; main effect of d
Inactive responses during contingency degradation testing with DO34, DO
session: χ2 = 3.5, P = .62; main effect of drug: χ2 = 0.57, P = .452; session‐b
of P < .001; * denotes a significance level of P < .053.2 | Impact of endocannabinoid drugs on habitual
behavior
Next, we tested the hypothesis that increasing endocannabinoid con-
centrations and subsequent CB1 receptor‐mediated signaling induces
ethanol self‐administration by testing the endocannabinoid transport
inhibitor AM404 and the CB1 receptor antagonist AM251. A naïve
cohort of mice (n = 15) underwent habit training (Figure 2A) and was
confirmed to be habitual. Then, mice underwent contingency degrada-
tion testing following administration of AM251, AM404, or vehicle.
AM404 administration reduced responding in the test compared with
vehicle (Figure 2B; P < .001), as did AM251 (P = .006). Responding fol-
lowing AM404 and AM251 administration were not significantly dif-
ferent from each other (P = .09). AM404 reduced total magazine
entries compared with vehicle (Figure 2C; P = .03), whereas AM251alcohol. A, Experimental timeline. B, Active response rate (left axis) and
response rate during contingency degradation testing with DO34,
: χ2 = 190.7, P < .001; main effect of drug: χ2 = 79.4, P < .001; session‐
contingency degradation testing with DO34, DO53, and vehicle
; main effect of drug: χ2 = 11.0, P = .004; session‐by‐drug interaction:
y degradation testing with DO34, DO53, and vehicle treatment within‐
rug: χ2 = 2.5, P = .3; session‐by‐drug interaction: χ2 = 2.9, P = .2. F,
53, and vehicle treatment within‐subjects, n = 16. Main effect of
y‐drug interaction χ2 = 0.592, P = .452. *** denotes a significance level
FIGURE 2 Habitual alcohol seeking responses depend on endocannabinoid system integrity. A, Active response rate (left axis) and earned
ethanol (g/kg, right axis) across operant ethanol training. B, Active response rate during contingency degradation testing with AM404, AM251,
and vehicle treatment within‐subjects, n = 15. Main effect of session: χ2 = 20.4, P < .001; main effect of drug: χ2 = 20.1, P < .001; session‐by‐drug
interaction: χ2 = 30.6, P < .001). C, Total magazine entries during contingency degradation testing with AM404, AM251, and vehicle treatment
within‐subjects, n = 15. Main effect of session: χ2 = 4.9, P = .03; main effect of drug: χ2 = 5.6, P = .06; session‐by‐drug interaction: χ2 = 8.2, P = .02.
D, Incentivized entries into the magazine during contingency degradation testing with AM404, AM251, and vehicle treatment within‐subjects,
n = 15. Main effect of session: χ2 = 10.0, P = .002; main effect of drug: χ2 = 6.6, P = .04; session‐by‐drug interaction: χ2 = 13.1, P = .001. E, Inactive
responses during contingency degradation testing with AM404, AM251, and vehicle treatment within‐subjects, n = 15. Main effect of session:
χ2 = 17.98, P < .001; main effect of drug: χ2 = 0.43, P = .81; session‐by‐drug interaction: χ2 = 2.79, P = .25*** denotes a significance level of
P < .001; ** denotes a significance level of P < .01; * denotes a significance level of P < .05
6 of 12 GIANESSI ET AL.administration did not differ from vehicle (P = .31) or AM404 (P = .6).
Both AM404 (Figure 2D; P = .008) and AM251 (P = .04) reduced
incentivized entries compared with vehicle treatment but were not
significantly different from each other (P = .6). Inactive responses
decreased from an average of 3.2 ± 0.5 SEM per session during the
baseline to an average of 1.5 ± 0.4 SEM per session during the contin-
gency degradation test (Figure 2E; main effect of session: χ2 = 17.98,
P < .001), but no effects of drugs or interactions were observed for
inactive responses.
3.3 | AM404 reduces habitual responding that is
insensitive to devaluation
As AM404 robustly reduced habitual ethanol seeking and consump-
tion in our contingency degradation paradigm, we next sought to con-
firm these findings using a second type of test for habit: reinforcer
devaluation via LiCl pairing. A naïve cohort of mice (n = 23) first
underwent habit training (Figure 3A) and were confirmed to be habit-
ual by contingency degradation and then underwent contingencydegradation testing in the presence of AM404 or vehicle. Consistent
with our previous experiment, AM404‐administration significantly
reduced habitual responding in the contingency degradation test com-
pared with the vehicle condition (Figure 3B; χ2 = 103.6, P < .001).
Administration of AM404 significantly reduced total magazine entries
during contingency degradation compared with that following vehicle
(Figure 3C; χ2 = 19.8, P < .001). Mice made fewer incentivized entries
following AM404‐treatment compared with vehicle treatment
(Figure 3D; χ2 = 32.9, P < .001). There was a significant reduction in
inactive responses following administration of AM404 (Figure 3E; P
< .001), from an average of 1.17 ± 0.3 SEM inactive responses per ses-
sion in baseline, to an average of 0.39 ± 0.2 SEM inactive responses
per session during test with AM404. In summary, AM404 reduced
habitual responding for ethanol, with a corresponding decrease in con-
sumption of ethanol and ethanol‐approach behavior, thereby replicat-
ing the previous behavioral results with AM404.
To confirm habitual responding in these mice with a secondary
assessment of habit, the mice were then divided into two conditions
matched on response rates during contingency degradation following
FIGURE 3 AM404 reduces habitual responding for alcohol in mice that are insensitive to devaluation. A, Active response rate (left axis) and
earned ethanol (g/kg, right axis) across operant ethanol training. B, Active response rate during contingency degradation testing with AM404
and vehicle treatment within‐subjects, n = 23. Main effect of session: χ2 = 50.6, P < .001; main effect of AM404: χ2 = 37.9, P < .001; session‐by‐
AM404 interaction: χ2 = 36.9, P < .001. C, Total magazine entries during contingency degradation testing with AM404 and vehicle treatment
within‐subjects, n = 23. Main effect of session: χ2 = 6.8, P = .009; main effect of AM404: χ2 = 15.0, P < .001; session‐by‐AM404 interaction:
χ2 = 21.9, P < .001. D, Incentivized entries into the magazine during contingency degradation testing with AM404 and vehicle treatment within‐
subjects, n = 23. Main effect of session: χ2 = 14.1, P < .001; main effect of AM404: χ2 = 20.8, P < .001; session‐by‐AM404 interaction: χ2 = 20.2,
P < .001. E, Inactive responses during contingency degradation testing with AM404 and vehicle treatment within‐subjects, n = 23. Main effect of
session: χ2 = 7.51, P = .006; main effect of drug: χ2 = 2.0, P = .16; session‐by‐drug interaction: χ2 = 4.1, P = .043. Post hoc tests revealed inactive
responses during baseline sessions were not significantly different across drug treatments (P = .46). Vehicle administration did not alter inactive
responses during the test compared with baseline (P = .51). AM404 reduced inactive responses in the test compared with inactive responses
during baseline (P = .001). F, LiCl devaluation experimental timeline. G, Active response rate during the habit test in extinction, between subjects
n = 12 saline‐paired, n = 11 LiCl‐paired. Main effect of drug: χ2 = 0.6, P = .4. H, Conditioned taste aversion consumption test, between subjects
n = 12 saline‐paired, n = 11 LiCl‐paired. *** denotes a significance level of P < .001; ** denotes a significance level of P < .01
GIANESSI ET AL. 7 of 12AM404 (valued vs devalued group: χ2 = 0.002, P = .96). Mice
underwent 3 days of devaluation (pairing LiCl with exposure to the
ethanol solution) or a control procedure (pairing saline with exposure
to the ethanol solution, see timeline Figure 3F), followed by an oper-
ant habit test and a conditioned taste aversion test. There was no dif-
ference in response rates between saline‐paired and LiCl‐paired
animals during the habitual responding test (Figure 3G; main effectof drug: χ2 = 0.6, P = .4). However, LiCl‐paired animals developed a
conditioned taste aversion for ethanol: LiCl‐paired animals drank less
ethanol than the saline‐paired ones (Figure 3H; t12 = 3.4, P = .006),
indicating devaluation procedures were successful. Thus, the
responding for ethanol (Figure 3G) was decoupled from the value of
the ethanol, confirming that the responses were habitual. These data
indicate that responding for ethanol in the contingency degradation
8 of 12 GIANESSI ET AL.was insensitive to reinforcer devaluation yet was reduced following
AM404 administration in the contingency degradation test.3.4 | Measuring the impact of increased 2‐AG and
anandamide on habitual responding
In order to better understand the mechanism by which AM404 pro-
duces its effects on responding, we tested whether increasing 2‐AG
or anandamide levels would produce similar reductions in habitual
responding. We tested JZL184, a drug that degrades the metabolic
enzyme for 2‐AG resulting in increased 2‐AG, and URB597, a drug
that degrades the metabolic enzyme for anandamide resulting in
increased anandamide, on habitual responding. We chose the 2
mg/kg dose of JZL184 because previously we reported that this dose
partially blocked the effect of AM404 on habitual food responding in
mice.32 A naïve cohort of mice (n = 26) underwent habit training
(Figure 4A), were confirmed to be habitual, and then administered
JZL184, URB597, and vehicle in a counterbalanced manner. There
were no effects of either drug on response rate (Figure 4B;
P = .955), magazine entries (Figure 4C; P = .11), incentivized entries
(Figure 4D; P = .6), or inactive responses (Figure 4E; P = .3).FIGURE 4 Habitual alcohol seeking responses not changed by FAAH or M
(g/kg, right axis) across operant ethanol training. B, Active response rate du
treatment, within subjects, n = 26. Main effect of session: χ2 = 3.521, P =
interaction: χ2 = 0.435, P = .8. C, Total magazine entries during contingenc
subjects, n = 26. Main effect of session: χ2 = 76.07, P < .001; main effect
P = .666. D, Incentivized entries into the magazine during contingency deg
n = 26. Main effect of session: χ2 = 0.088, P = .766; main effect of drug: χ2
responses during contingency degradation testing with URB597, JZL184,
P = .71; main effect of drug: χ2 = 2.3, P = .3; session‐by‐drug interaction χ3.5 | Measuring the impact of 2‐AG release on
progressive ratio responding
Because AM404, AM251, and DO34 reduced approach behaviors
along with ethanol‐seeking responses, we hypothesized that 2‐AG
may mediate motivation to seek ethanol. One behavioral metric for
quantifying motivation is measuring responding using a progressive
ratio schedule of reinforcement, where the effort required to earn a
single reinforcer progressively increases across a session. To deter-
mine if increasing 2‐AG increased motivation for ethanol, we trained
a naïve cohort of mice (n = 12) on a progressive ratio schedule of rein-
forcement, and administered, in a counterbalanced order, vehicle and
three doses of JZL184. The rewards earned following 2 mg/kg
JZL184 were not different from vehicle treatment (Figure 5A;
χ2 = 3.6, P = .2). The 8 and 18 mg/kg doses of JZL184 increased
rewards earned compared with vehicle treatment (8 mg/kg: χ2 = 8.8,
P = .009; 18 mg/kg: χ2 = 10.9, P = .003). The 2 mg/kg dose of
JZL184 did not significantly alter response rate on progressive ratio
compared with vehicle treatment (Figure 5B; χ2 = 3.7, P = .2), but both
8 mg/kg (χ2 = 6.3, P = .04) and 18 mg/kg (χ2 = 6.7, P = .03) doses of
JZL184 increased total responses made compared with vehicle
treatment.AGL inhibition. A, Active response rate (left axis) and earned ethanol
ring contingency degradation testing with URB597, JZL184, or vehicle
.061; main effect of drug: χ2 = 0.092, P = .955; session‐by‐drug
y degradation testing with URB597, JZL184, and vehicle, within
of drug: χ2 = 4.48, P = .11; session‐by‐drug interaction: χ2 = 0.814,
radation testing with URB597, JZL184, and vehicle, within subjects,
= 1.0, P = .6; session‐by‐drug interaction: χ2 = 1.7, P = .44. E, Inactive
and vehicle, within subjects, n = 26. Main effect of session: χ2 = 0.14,
2 = 3.1, P = .21. *** denotes a significance level of P
FIGURE 5 Increasing 2‐AG amplifies motivation to work for alcohol. A, Rewards earned during a drug‐free baseline progressive ratio session
compared with those earned following vehicle, 2, 8, or 18 mg/kg JZL184, within subjects, n = 12. Main effect of session: χ2 = 4.8, P = .03;
main effect of dose: χ2 = 19.7, P < .001; session‐by‐dose interaction: χ2 = 11.7, P = .009. B, Total active responses made during a drug‐free
baseline progressive ratio session compared with responses following vehicle, 2, 8, or 18 mg/kg JZL184, within subjects, n = 12. Main effect of
session: χ2 = 17.4, P < .001; main effect of dose: χ2 = 28.0, P < .001; session‐by‐dose interaction: χ2 = 19.9, P < .001. *** denotes a significance
level of P < .001; * denotes a significance level of P < .05
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These data provide novel evidence for the role for 2‐AG in regulating
the expression of habitual ethanol seeking, as well as in the motivation
to obtain ethanol. We combined the innovative application of statisti-
cal methods with advanced behavioral analyses and pharmacology to
provide empirical support that endocannabinoid‐mediated CB1 recep-
tor signaling is necessary for the expression of habitual ethanol seek-
ing. This is the first study, to our knowledge, to examine effects of
DO34, a novel DAGLs inhibitor, on ethanol‐motivated behavior. These
data provide insights into the physiology of habitual ethanol seeking in
mice and may provide a novel therapeutic mechanism for research
aimed at the development of treatments for AUD.
Here, we show that the endocannabinoid transport inhibitor
AM404 results in a robust and replicable reduction in habitual ethanol
seeking and ethanol approach behavior. This finding extends previous
results demonstrating that AM404 decreases ethanol self‐
administration on an FR schedule of reinforcement that was presum-
ably goal directed because this schedule of reinforcement is unlikely
to produce habitual responding.31 Previous work from our lab has
shown that this dose of AM404 does not affect locomotor activity.32
Critically, we found that AM404 was able to reduce habitual ethanol
seeking and incentivized entries for ethanol. Our data showing that
AM404 could attenuate ethanol habits also were replicated in a sec-
ond cohort of mice that were shown to be insensitive to LiCl devalu-
ation of ethanol, which confirms that the ethanol‐seeking behavior
was no longer tied to the value of the ethanol. These results may sug-
gest a high translational value for the effect of AM404 because the
compulsive, habitual alcohol seeking that is observed in AUD is
hypothesized to result from drinking that is no longer tied to the value
of the alcohol.
The mechanism of action of AM404 in alcohol self‐administration
models is currently unknown. Previously, it has been shown that themechanism of AM404‐induced reductions in ethanol self‐
administration was not due to indirect activation of the cannabinoid
CB1, CB2, nor the transient receptor potential vanilloid‐1 (TRPV1)
receptors.31 This suggests that AM404 does not increase
endocannabinoid levels in the synapse within the context of ethanol
self‐administration. This possibility aligns with our observed lack of
effect of administration of URB597 or low‐dose JZL184 on ethanol
habit—if AM404 was acting by increasing these endocannabinoids,
we would have observed a similar reduction in habitual responding.
Previously, it has been found that AM404 can prevent the release of
endocannabinoids under certain conditions via inhibition of the puta-
tive endocannabinoid transporter.38-40 Given that ethanol self‐
administration does increase 2‐AG release,24 we tested the hypothesis
that a reduction in synaptic release of 2‐AG and subsequent reduced
CB1 receptor‐mediated signaling may reduce ethanol self‐
administration. Consistent with this hypothesis, we report that inhibi-
tion of 2‐AG biosynthesis with DO34 and antagonism of the CB1
receptor with AM251 potently reduced habitual ethanol seeking.
Thus, in light of these findings, we suggest that the ability of AM404
to reduce habitual ethanol‐seeking behavior may be due to inhibition
of 2‐AG release from the postsynaptic site, thereby mimicking the
effect of DO34 and AM251. However, we cannot rule out the possi-
bility that AM404 could be signaling at other targets such as the
TRPV1 receptor.41 Intriguingly, our previous work has demonstrated
that AM404 reduced habitual food seeking, yet this effect was abro-
gated with pretreatment of with a high dose of JZL184,32 suggesting
bidirectional modulation of habitual responding by endocannabinoids.
More extensive characterization of potential dose‐dependent effects
of anandamide and 2‐AG signaling are warranted.
Of note, previous studies using in vivo microdialysis have reported
a potentiation of ethanol‐induced 2‐AG release following AM404
administration.23 There are several differences in experimental design
that may explain the disparity between this study and our data. First,
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administered as in our studies, and there is evidence that route of eth-
anol administration has divergent effects on 2‐AG.24 Second, 2‐AG
release was assessed in a new context, whereas our experiments took
place in the same context as ethanol self‐administration. Alcohol‐
associated contextual cues are sufficient to produce habitual
responding42 and are therefore important to consider. Additionally,
Alvarez‐Jaimes and colleagues23 used a model of ethanol physical
dependence prior to the microdialysis measurements, whereas our
operant model may not create such physical dependence. Furthermore,
if AM404 potentiated the 2‐AG release in our experiment, this result
would be in direct conflict with several of our other findings for the fol-
lowing reasons: if higher levels of synaptic 2‐AG were responsible for
the reductions in habitual ethanol seeking and approach observed with
AM404, then we would expect DO34 (which inhibits the enzymes that
synthesize 2‐AG) to increase habitual responding for ethanol. DO34,
however, reduced habitual responding. Moreover, if AM404 increased
synaptic levels of 2‐AG, we would expect that JZL184 (which inhibits
the enzymes that metabolize 2‐AG) would decrease motivation for eth-
anol; however, JZL184 increased motivation for ethanol as assessed by
progressive ratio responding. Collectively, our results are more consis-
tent with the hypothesis that AM404 blocked the release of 2‐AG,
which reduced the motivation to seek and drink ethanol by reducing
signaling through the CB1 receptor. Nevertheless, this hypothesis war-
rants further investigation.
Our results provide support for pharmacological strategies to
reduce pathological habitual behaviors in AUD that may benefit from
moderating the influence of 2‐AG release. Clinical studies assessing
treatment efficacy of CB1 receptor antagonists for reducing alcohol
consumption or preventing relapse have not reached statistical
significance, perhaps due to the incomplete occupancy of the CB1
receptor at the moderate dose administered in the studies.43,44 Unfor-
tunately, higher doses of the CB1 antagonist could not be tested due
to negative on‐target psychiatric side effects.43 It is possible that
drugs that inhibit the putative endocannabinoid transporter might
have a more favorable risk‐to‐benefit profile than CB1 receptor
antagonists. Indeed, AM404 does not change synaptic levels of
endocannabinoids on its own45 but instead inhibits the release or
clearance of endocannabinoids. AM404 may hold particular promise
in treating AUD because it is an active metabolite of
acetaminophen/paracetamol46 and, thus, could potentially be used
clinically.
The effects observed with JZL184 and DO34 are particularly
important for understanding the role for 2‐AG in ethanol‐motivated
behavior. DO34, but not DO53, reduced habitual ethanol seeking
and approach behavior, which demonstrates the necessity of 2‐AG
for the expression of ethanol habits. Previous work demonstrated that
both DO34 and DO53 were able to reduce food intake and alter
metabolism,25 which suggests that, in contrast to food, the effect of
DO34 on ethanol‐motivated behavior may be a 2‐AG specific effect.
Increasing 2‐AG levels with JZL184 increased breakpoint for ethanol
in our study, and previously similar results were found with progres-
sive ratio for food,47 suggesting that 2‐AG may contribute to themotivation to work for caloric reinforcers in general. Furthermore, a
recent study demonstrated that stress‐induced increases in 2‐AG sig-
naling within the prelimbic cortex promoted cocaine seeking behav-
ior,48 suggesting the possibility that 2‐AG signaling is involved in
hedonic reinforcement aside from caloric reinforcers as well. Our pro-
gressive ratio data with JZL184 may complicate MAGL inhibition as an
anxiolytic target, because alcohol use disorder or other substance use
disorders are often comorbid with anxiety disorders, particularly post-
traumatic stress disorder.49,50 It would be problematic if administra-
tion of a MAGL inhibitor alleviated the anxiety disorder, but
worsened the AUD. A recent study reported low doses (1 and
3 mg/kg) of JZL184 alleviated anxiety‐related behaviors in ethanol‐
dependent mice.51 Our progressive ratio results may suggest caution
for the use of higher doses of JZL184 for treatment of anxiety to pre-
vent increasing motivation for ethanol; however, the low 2 mg/kg
dose of JZL184 did not increase motivation for ethanol or alter the
expression of ethanol seeking habits. Together, these results indicate
a putative critical and selective role for 2‐AG in habitual ethanol
seeking.
The current study provides evidence for endocannabinoid signaling
processes that mediate habitual alcohol seeking and consumption in
mice. We propose that 2‐AG release contributes to the motivation
to seek ethanol and to the expression of ethanol habits, and argue
that pharmacological approaches to moderating 2‐AG signaling may
be fruitful for the treatment of pathological habitual alcohol seeking
characteristic of AUD.
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